Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis: A Multinational, Prospective, Controlled, Randomized Trial

Authors

Julie Thompson
Natasha Jones
Ali Al-Khafaji
Shahid Malik
David Reich
Santiago Munoz
Ross MacNicholas
Tarek Hassanein
Lewis Teperman
David Wolf, New York Medical CollegeFollow
VTI-208 Study Group

Journal Title

Liver Transplantation

First Page

380

Last Page

393

Document Type

Article

Publication Date

March 2018

Department

Medicine

Abstract

Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin >/=8 mg/dL, Maddrey's discriminant function >/= 32, and Model for End-Stage Liver Disease (MELD) score

Comments

Please see the work for the complete list of authors.

Recommended Citation

Thompson, J., Jones, N., Al-Khafaji, A., Malik, S., Reich, D., Munoz, S., MacNicholas, R., Hassanein, T., Teperman, L., Wolf, D., & VTI-208 Study Group. (2018). Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis: A Multinational, Prospective, Controlled, Randomized Trial. Liver Transplantation, 24 (3), 380-393. https://doi.org/10.1002/lt.24986